Surefire Medical launches cancer drug delivery catheter

Westminister, CO's Surefire Medical launched a drug delivery catheter for for direct-to-tumor embolization procedures. "Chemo- and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors. The Precision catheter provides us with a new interventional tool to safely and effectively deliver drug eluting and yttrium-90 microspheres within the tumor," said Dr. Geert Maleux of the department of radiology at University Hospitals in Leuven, Belgium. The company says a study found the device increases drug delivery into tumors by 90% and reduced delivery to healthy tissue. The Precision catheter has a CE mark and FDA clearance, enabling commercialization in the U.S. and Europe. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.